Src kinase inhibitors: an emerging therapeutic treatment option for prostate cancer

Edwards, J. (2010) Src kinase inhibitors: an emerging therapeutic treatment option for prostate cancer. Expert Opinion on Investigational Drugs, 19(5), pp. 605-614. (doi: 10.1517/13543781003789388)

Full text not currently available from Enlighten.

Abstract

Areas covered in this review: Here, current treatment options for advanced prostate cancer, the preclinical rationale behind using Src inhibitors, emerging data from clinical trials of Src inhibitors in prostate cancer, and future therapeutic directions are described. Data published in peer-reviewed journals within the last 20 years or presented at recent European or American Society of Clinical Oncology conferences have been reviewed. What the reader will gain: Readers will gain an insight into the development of therapeutic Src inhibitors, including dasatinib and saracatinib; an understanding of their effects on prostate cancer cells and the bone microenvironment; and emerging clinical data. Take home message: Src is implicated in prostate cancer progression and metastasis, therefore treatment with Src inhibitors warrants further investigation

Item Type:Articles
Keywords:AMERICAN-SOCIETY ANDROGEN-RECEPTOR BONE METASTASES C-SRC CANCER CARE CELLS clinical trials CLINICAL-TRIALS ENGLAND FAMILY KINASES FOCAL ADHESION KINASE GENE HORMONAL-THERAPY IN-VITRO INHIBITOR LEVEL metastasis OSTEOCLAST FUNCTION pharmacology PROGRESSION RATIONALE Scotland SIGNAL-TRANSDUCTION PATHWAYS Treatment TRIAL trials ZOLEDRONIC ACID
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Edwards, Professor Joanne
Authors: Edwards, J.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cancer Sciences
Journal Name:Expert Opinion on Investigational Drugs
ISSN:1354-3784

University Staff: Request a correction | Enlighten Editors: Update this record